146 related articles for article (PubMed ID: 26366623)
1. Prognostic relevance of CD20 expression in peripheral T-cell lymphomas: a multi-center retrospective study.
Toya T; Nannya Y; Hangaishi A; Shiseki M; Shimoyama T; Sakamaki H; Motoji T; Usuki K; Nakamura F; Kurokawa M
Leuk Lymphoma; 2016; 57(4):961-4. PubMed ID: 26366623
[No Abstract] [Full Text] [Related]
2. The prognostic value of interim and end-of-treatment PET/CT in patients with newly diagnosed peripheral T-cell lymphoma.
Ham JS; Kim SJ; Choi JY; Hyun SH; Choi SK; Kim HS; Lim SH; Lee JY; Jung SH; Ko YH; Kim WS
Blood Cancer J; 2016 Feb; 6(2):e395. PubMed ID: 26871713
[No Abstract] [Full Text] [Related]
3. Phase I dose escalation study of the anti-CD2 monoclonal antibody, siplizumab, with DA-EPOCH-R in aggressive peripheral T-cell lymphomas.
Roswarski J; Roschewski M; Lucas A; Melani C; Pittaluga S; Jaffe ES; Steinberg SM; Waldmann TA; Wilson WH
Leuk Lymphoma; 2018 Jun; 59(6):1466-1469. PubMed ID: 29032710
[No Abstract] [Full Text] [Related]
4. Loss of CD3 and TCRγδ expression in a relapsed hepatosplenic T-cell lymphoma.
Hodkoff A; Bentley P; Xu X
Leuk Lymphoma; 2018 Feb; 59(2):479-481. PubMed ID: 28573906
[No Abstract] [Full Text] [Related]
5. Composite diffuse large B-cell lymphoma and CD20-positive peripheral T-cell lymphoma.
Yamazaki S; Fujioka Y; Nakamura F; Ota S; Shinozaki A; Yamamoto G; Kamikubo Y; Nannya Y; Ichikawa M; Fukayama M; Kurokawa M
Pathol Int; 2011 Nov; 61(11):662-6. PubMed ID: 22029677
[TBL] [Abstract][Full Text] [Related]
6. Expression of constitutively activated NF-κB/mTORC pathway proteins and response to CHOP with bortezomib in a patient with angioimmunoblastic peripheral T-cell lymphoma.
Quesada AE; Rios A; Brown RE; Nguyen ND
Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S87-9. PubMed ID: 25486962
[No Abstract] [Full Text] [Related]
7. [Diagnosis and treatment of peripheral T-cell lymphoma].
Suzumiya J; Moriyama I; Kawakami K
Nihon Rinsho; 2012 Apr; 70 Suppl 2():519-24. PubMed ID: 23134009
[No Abstract] [Full Text] [Related]
8. [Primary lymphoma of breast: a clinicopathologic and prognostic study of 40 cases].
Yang H; Lang RG; Liu FF; Wang XF; Jin ZJ; Lü AJ; Wang Y; Fu XL; Fu L
Zhonghua Bing Li Xue Za Zhi; 2011 Feb; 40(2):79-84. PubMed ID: 21426801
[TBL] [Abstract][Full Text] [Related]
9. [Recent advance in peripheral T-cell lymphoma, not otherwise specified].
Duan R; Zhang JZ
Zhonghua Bing Li Xue Za Zhi; 2010 Jun; 39(6):427-9. PubMed ID: 21055168
[No Abstract] [Full Text] [Related]
10. Phase I study of vorinostat in combination with standard CHOP in patients with newly diagnosed peripheral T-cell lymphoma.
Oki Y; Younes A; Copeland A; Hagemeister F; Fayad LE; McLaughlin P; Shah J; Fowler N; Romaguera J; Kwak LW; Pro B
Br J Haematol; 2013 Jul; 162(1):138-41. PubMed ID: 23590726
[No Abstract] [Full Text] [Related]
11. Peripheral T-cell lymphoma, NOS, with rapidly progressing leukocytosis mimicking acute lymphoblastic leukemia.
Jelinek T; Zuchnicka J
Blood; 2020 May; 135(20):1816. PubMed ID: 32407530
[No Abstract] [Full Text] [Related]
12. Optimising initial treatment for peripheral T-cell lymphoma: a tough nut to CHOP.
Wilcox RA
Lancet Haematol; 2018 May; 5(5):e182-e183. PubMed ID: 29703333
[No Abstract] [Full Text] [Related]
13. Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas.
Fanale MA; Horwitz SM; Forero-Torres A; Bartlett NL; Advani RH; Pro B; Chen RW; Davies A; Illidge T; Uttarwar M; Lee SY; Ren H; Kennedy DA; Shustov AR
Blood; 2018 May; 131(19):2120-2124. PubMed ID: 29507077
[TBL] [Abstract][Full Text] [Related]
14. Thoracic subcutaneous infiltration: an unusual presentation of subcutaneous panniculitis-like T-cell lymphoma.
Ballanger F; Barbarot S; Le Gouill S; Gaillard F; Cassagnau E; Lodé L; Dréno B; Stalder JF
Acta Derm Venereol; 2009; 89(4):427-9. PubMed ID: 19688166
[No Abstract] [Full Text] [Related]
15. High thymidine kinase activity is a strong predictive factor for poor prognosis in peripheral T-cell lymphoma treated with cyclophosphamide, adriamycin, vincristine and prednisone.
Suzuki K; Terui Y; Nakano K; Nara E; Nasu K; Ueda K; Nishimura N; Mishima Y; Sakajiri S; Yokoyama M; Takahashi S; Hatake K
Leuk Lymphoma; 2012 May; 53(5):849-54. PubMed ID: 22035416
[TBL] [Abstract][Full Text] [Related]
16. [Small cell variant of peripheral T-cell lymphoma, not otherwise specified: a clinicopathologic and immunophenotypic analysis].
Li YL; Liu WP; Tang Y; Zhao S; Zuo Z; Yang YH; Yang QP; Luo TY
Zhonghua Bing Li Xue Za Zhi; 2009 May; 38(5):323-8. PubMed ID: 19575875
[TBL] [Abstract][Full Text] [Related]
17. Increased rituximab (R) doses eliminate increased risk and improve outcome of elderly male patients with aggressive CD20+ B-cell lymphomas: the SEXIE-R-CHOP-14 trial of the DSHNHL.
Clin Adv Hematol Oncol; 2014 Aug; 12(8 Suppl 16):8-9. PubMed ID: 25768993
[No Abstract] [Full Text] [Related]
18. Comparison of International Prognostic Index and NCCN-IPI in 324 patients with de novo diffuse large B-cell lymphoma: a multi-center retrospective analysis.
Öztürk E; Özbalak M; Berk S; Erdoğan I; Avşar E; Dolgun A; Çetiner M; Mandel NM; Yalnız FF; Elverdi T; Salihoğlu A; Eşkazan AE; Ar MC; Öngören Ş; Başlar Z; Aydın Y; Soysal T; Ferhanoğlu B
Leuk Lymphoma; 2016 May; 57(5):1211-4. PubMed ID: 26294270
[No Abstract] [Full Text] [Related]
19. [Recent advance in peripheral T-cell lymphoma, not otherwise specified].
Zhan HQ; Li XQ; Zhu XZ
Zhonghua Bing Li Xue Za Zhi; 2010 May; 39(5):353-6. PubMed ID: 20654164
[No Abstract] [Full Text] [Related]
20. [Clinical features and prognostic factors of angioimmunoblastic T cell lymphoma].
Qin Y; Shi YK; He XH; Yang JL; Zhang CG; Zhou SY; Liu XF; Liu P; Yang S; Zhou LQ; Han XH; Yao JR
Zhonghua Zhong Liu Za Zhi; 2010 Jun; 32(6):448-51. PubMed ID: 20819488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
